Influence of formulation properties on chemical stability of captopril in aqueous preparations.
The influence of various formulation properties on the chemical stability of captopril in aqueous media at pH 3 was investigated, in order to reformulate and increase the shelf-life of an oral mixture of the drug. At this pH, chemical stability is improved by an increase in drug concentration (1-5 mg/ml) and a decrease in temperature (5-36 degrees C), the latter demonstrated by a linear Arrhenius-plot. The activation energy is low (Ea = 10.2 kcal/mol), thus the Q10 value is only 1.8 in pure aqueous solutions. The degradation at the lowest concentration investigated in pure aqueous solution apparently follows zero order kinetics. The reaction order is changed at higher concentrations. We are presenting a hypothesis of intramolecular proton transfer from the thiol to the ionized carboxylic group as the initial step in the oxidative degradation pathways of captopril. Long-term stability of 1 mg/ml captopril in aqueous solutions at pH 3, stored at 36 degrees C for one year, shows that the sugar alcohol sorbitol accelerates degradation of the drug while Na-EDTA at a concentration as low as 0.01% is sufficient to stabilize these samples. Purging with N2-gas prior to storage is not essential for drug stability, as long as Na-EDTA is present. Only at a low level of Na-EDTA (0.01%) combined with a high level of sorbitol (35%), purging with N2-gas appears to have a small effect. The destabilizing effect of sugar alcohols is confirmed by accelerated degradation also in the presence of glycerol. The efficient stabilization in the presence of Na-EDTA at a low concentration indicates that the metal-ion-catalyzed oxidation pathway dominates the chemical degradation process at low pH, although several mechanisms seem to be involved depending on excipients present.
Kristensen
S
S
University of Oslo, School of Pharmacy, Department of Pharmacy, Oslo, Norway. solveig.kristensen@farmasi.uio.no
Lao
Y E
YE
Brustugun
J
J
Braenden
J U
JU
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000737:chemistry*; D002021:Buffers; D002216:Captopril / Q000008:administration & dosage / Q000737:chemistry*; D002384:Catalysis; D002614:Chelating Agents / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D004356:Drug Storage; D005079:Excipients; D006358:Hot Temperature; D006863:Hydrogen-Ion Concentration; D010100:Oxygen / Q000737:chemistry; D011522:Protons; D012996:Solutions; D012997:Solvents; D013056:Spectrophotometry, Ultraviolet; D014867:Water
D000806:Angiotensin-Converting Enzyme Inhibitors; D002021:Buffers; D002614:Chelating Agents; D005079:Excipients; D011522:Protons; D012996:Solutions; D012997:Solvents; D014867:Water; D002216:Captopril; D010100:Oxygen